



CalRx® Insulin Patient Advisory Council Kickoff
Insulin Market Discussion Questions
Tuesday, April 29, 2025

1. Ensuring Equitable Insulin Access & Affordability

- a. What is top of mind for you in ensuring equitable access to insulin?
- b. What is top of mind for you regarding insulin affordability?
- c. What other challenges do consumers face regarding insulin availability and managing their treatment regimen?

2. Biosimilar vs. Brand Insulin Preference

We would like to better understand the potential barriers to accessing more affordable, FDA-approved biosimilar insulins, such as formulary coverage by pharmacy benefit managers (PBMs) and consumer concerns about efficacy.

- a. What are the key barriers to uptake of biosimilar insulins?
- b. How do consumers perceive the effectiveness of biosimilar insulins?
- c. Are there patient education models, frameworks, or resources that you've found useful in alleviating consumer concerns about biosimilar insulins?
- d. What do insured patients experience when their health plan changes the formulary, and their current insulin is now listed as "not covered"?

3. Mail Order vs. Community Pharmacy Preference

We would like to better understand the potential barriers to accessing community pharmacies and utilizing mail-order pharmacies, such as the logistics of cold-chain transport and the need for insulin to be temperature controlled at the point of delivery (i.e., not sitting out for excessive periods).

- a. How does the location or convenience of community pharmacies impact consumer access to insulin?
- b. How do consumers perceive the use of mail-order pharmacies for accessing insulin?
- c. What are the key barriers to uptake of mail-order pharmacies for accessing insulin?



4. Feedback on Existing Insulin Discount & Access Programs

We would like to better understand the potential barriers to participating in insulin discount and access programs, such as discount cards or copay programs.

- a. What do consumers experience when navigating participation in these programs?
- b. For those of you that work in advocacy, how are insulin manufacturers responding to concerns about barriers to accessing these programs?
- c. How do consumers perceive the use of direct-to-consumer models being offered by insulin manufacturers (e.g., Lilly Direct)?